Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics
about
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyAmyloid-β Receptors: The Good, the Bad, and the Prion ProteinAlzheimer's Disease: Mechanism and Approach to Cell TherapyFrailty and the risk of cognitive impairmentAmyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce CytotoxicityVincamine Alleviates Amyloid-β 25-35 Peptides-induced Cytotoxicity in PC12 CellsBrain amyloid in preclinical Alzheimer's disease is associated with increased driving risk.Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's diseaseMitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease.Rosetta Stone for Amyloid Fibrils: The Key Role of Ring-Like Oligomers in Amyloidogenesis.Kinesin-1 inhibits the aggregation of amyloid-β peptide as detected by fluorescence cross-correlation spectroscopy.Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.The Proteasome and Oxidative Stress in Alzheimer's Disease.A Mitocentric View of Alzheimer's Disease.Production of Monoclonal Antibodies to Pathologic β-sheet Oligomeric Conformers in Neurodegenerative Diseases.Identification of key regions and residues controlling Aβ folding and assembly.Reversibility of Aβ oligomer neurotoxicity.Identifying Cu(ii)-amyloid peptide binding intermediates in the early stages of aggregation by resonance Raman spectroscopy: a simulation study.The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers.Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure.Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to Aβ immunotherapy.Inhibiting the Ca2+ Influx Induced by Human CSF.Amylin in Alzheimer's disease: Pathological peptide or potential treatment?Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.Investigation of the Subcellular Neurotoxicity of Amyloid-β Using a Device Integrating Microfluidic Perfusion and Chemotactic Guidance.An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging.The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits.
P2860
Q26747107-AC877C4B-74F9-4868-83E1-F8B99AA99E29Q26771532-25101D76-0BBC-40A2-97CA-F4D2504E9458Q26778149-8162267B-DE69-4D4A-B296-C09E90E83348Q26799300-6DFADC6C-AC10-4662-9BD0-105947C3359BQ35327172-F574A12E-0623-4322-917A-E25448803922Q35662361-D04B5529-C9B3-4252-87FF-79FFED1AB2C9Q37640781-B03037F4-623B-4819-9A8A-ED63E3540515Q37653343-37C58D05-F21A-4A7C-9DF0-8FBB9135CC46Q38590807-C8BCD26E-A0DF-498F-8778-02907E111D59Q38607493-448C1C9F-63E8-4BCE-B84E-6B211CEAEA76Q38663628-EC7EDE3E-AF8E-46A3-8336-82A9068AFAC5Q38785115-642A08B2-5896-48C5-AC8E-FDBCCE8E9644Q38807908-E1F1D11E-96DB-4C5F-B085-D310FA17A4A9Q38843876-82DB1271-8FC9-4E10-9A95-A7AA8856D9FAQ38970508-2929C500-45DC-40F1-BA17-31D70FA3B0DEQ41548991-AE48946F-C667-4FC2-B0FA-DEF75168CFD9Q42094428-A54B1B8C-3E6B-46B5-8113-39751466BAE4Q42353751-B01712CD-AC32-478F-AEC9-42CC4F9AFD7BQ46261288-009F13CC-96F1-4082-9658-7162AF3E9C4FQ46310832-30BE2A25-C534-40D6-B5A9-27D2E7F6FD44Q46341580-E90C8393-A2BE-4D0D-B59F-A3FF72B8A5A4Q46404042-4996F13D-FCE2-4BC9-B26E-EE6D2C6CA038Q46558453-E3ACB066-BB88-450D-BF41-0D63E424C77AQ47144784-FF57B266-6715-4935-A461-0D50D137C9DAQ47322028-84656BDD-0E1E-4A51-A178-189A4E741846Q48113629-7374E94D-340C-474C-8CB8-023184919005Q48340658-E2F69BBA-5B0A-48B8-9194-F58898BFEC05Q52653207-7CB3AF40-7867-44B1-887B-318A0C2BFC83Q54977832-374CEF68-9C0C-4F0A-AB60-FC3AF6D85AFBQ55353865-70B52028-A189-448A-BA3B-DAEB20C4189D
P2860
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@ast
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@en
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@nl
type
label
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@ast
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@en
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@nl
prefLabel
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@ast
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@en
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@nl
P2093
P2860
P3181
P356
P1476
Targeting the proper amyloid-b ...... r's disease immunotherapeutics
@en
P2093
Franz Hefti
Grant A Krafft
Jasna Jerecic
William F Goure
P2860
P2888
P3181
P356
10.1186/ALZRT272
P407
P577
2014-01-01T00:00:00Z
P5875
P6179
1047003180